Late-Occurring Vancomycin-Associated Acute Kidney Injury in Children Receiving Prolonged Therapy by Knoderer, Chad A. et al.
Late-Occurring Vancomycin-Associated Acute Kidney Injury in Children 
Receiving Prolonged Therapy 
    Chad A. Knoderer, PharmD 
    Allison L. Gritzman 
 Kristen R. Nichols, PharmD 
    Amy C. Wilson, MD 
Abstract: 
Background: Acute kidney injury (AKI) in patients receiving vancomycin has been associated with 
trough concentrations ≥15 mg/L and longer therapy duration. The objective of this study was to determine 
the incidence and factors associated with late AKI in children receiving ≥8 days of vancomycin therapy. 
Methods: Children aged 30 days to 17 years who were admitted to our institution and received 
intravenous vancomycin for at least 8 days during January to December of 2007 and 2010 and had a 
suspected or proven gram-positive infection were included. Late AKI was categorized as AKI occurring 
after the first 7 days of therapy and within 48 hours following vancomycin discontinuation. The primary 
outcome was incidence of late AKI as determined by modified pRIFLE criteria. Results: One-hundred 
sixty-seven patients were included, with a median (interquartile range) age (years) and weight (kg) of 2 
(1-7) and 12.5 (8.9-23.8). Late AKI was identified in 12.6% (21/167). A higher percentage of late AKI 
patients received concomitant treatment with intravenous acyclovir, amphotericin products, or 
piperacillin-tazobactam. Age <1 year was the only factor independently associated with late AKI 
development (odds ratio = 4.4; 95% confidence interval = 1.3-15.4). Conclusions: Late AKI occurred in 
nearly 13% of children receiving ≥8 days of vancomycin therapy. This study suggests that vancomycin 
trough concentrations are not associated with late AKI, but that age <1 year and concomitant 
administration of certain nephrotoxins may be factors associated with increased risk. 
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Background 
Vancomycin is a glycopeptide antibiotic commonly used to treat gram-positive infections, 
including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Following 
consensus recommendations for increased vancomycin dosing, more scrutiny has been directed 
toward vancomycin-associated acute kidney injury (AKI).1 Many studies have been performed to 
characterize AKI and determine AKI-associated factors in both adult and pediatric cohorts 
receiving vancomycin.2-11 Carreno and colleagues presented a thorough review of the history of 
vancomycin and nephrotoxicity and provided a comprehensive discussion of studies examining 
AKI in adult patients. Their review suggested that optimal strategies for safe vancomycin use are 
still unclear and recommended careful consideration of various risk factors for nephrotoxicity in 
patients receiving vancomycin.12 
In children, vancomycin has been traditionally empirically dosed as 40 mg/kg/day in 4 divided 
doses. Pediatric evidence and adult consensus recommendations published in 2009 through 2011 
suggested that higher starting doses (eg, 60 mg/kg/day) may be necessary to achieve serum trough 
concentrations corresponding to the optimal area under the curve (AUC) for plasma concentration 
relative to the organism minimum inhibitory concentration (MIC).13-15 Subsequently, pediatric 
reports emerged suggesting increased incidence of AKI.7,8 Relative to data in adults, there are 
fewer pediatric studies evaluating vancomycin-associated AKI, though similar trends have been 
observed with respect to AKI-associated factors. In some studies, vancomycin-associated AKI in 
children has been associated with trough concentrations ≥15 mg/L and longer treatment duration.7-
9 A conflicting study performed in critically ill children observed that sustained trough 
concentrations ≥15 mg/L are not associated with increased AKI.11 Many of the pediatric studies 
adopted an interpretation of the pRIFLE (pediatric risk, injury, failure, loss, and end-stage renal 
disease) criteria to define AKI by utilizing baseline and postinitiation serum creatinine (SCr) 
concentration data.7, 9,10,16 None of the currently available pediatric studies specifically addresses 
the factors associated with late-occurring AKI in patients receiving prolonged courses of 
vancomycin. The objective of this study was to determine the incidence and factors associated 
with AKI in children receiving ≥8 days of vancomycin therapy.  
Methods 
Study Design and Population 
This was a retrospective, single-center cohort study performed following approval from the 
institutional review boards at Indiana University and Butler University. Patients aged 30 days 
through 17 years who received vancomycin for at least 8 days for a suspected or proven gram-
positive infection were eligible for inclusion. Patients included received vancomycin during the 
calendar years 2007 and 2010, and these times represented periods before and after the 
recommended empiric vancomycin dosing was changed from 40 mg/kg/day to 60 mg/kg/day 
within our institution. It is important to note that despite these dose recommendations, empiric 
doses during both time periods ultimately remained at the discretion of individual prescribers in 
the course of routine practice.  
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Our goal in this study was to characterize late-occurring vancomycin-associated AKI. Since 
included patients received vancomycin for at least 8 days, we stratified patients into 2 groups. We 
defined early AKI as any AKI that occurred within the first 7 days of vancomycin therapy. Late 
AKI was defined as AKI that occurred at any time from day 8 and beyond of vancomycin therapy. 
We then excluded patients characterized as having early AKI to specifically examine the patients 
who experienced AKI later in the course of their vancomycin therapy—“late AKI” patients. 
Exclusions were made for patients with baseline SCr above institutional age-adjusted normal 
values (Table 1) prior to vancomycin initiation and for patients with either no baseline or no 
follow-up SCr obtained during the vancomycin course. Receipt of dialysis or extracorporeal 
membrane oxygenation was not a specific exclusion criterion. Baseline SCr was defined as a SCr 
obtained within 48 hours prior to initiating vancomycin therapy. Patients with an underlying 
diagnosis of cystic fibrosis were also excluded due to their altered pharmacokinetic properties of 
other antibiotics and potential need for higher vancomycin doses. In the instance where a patient 
received multiple vancomycin courses during the same hospitalization, only data from the first 
vancomycin course was recorded.  
Baseline demographic and clinical data, vancomycin dosing information, and history of exposure 
to other factors known to be associated with risk of AKI (ie, intensive care unit admission, 
extracorporeal membrane oxygenation utilization, sepsis) were extracted from medical records of 
eligible patients. Coding information from the institution’s information management system was 
used to identify patients with sepsis. Receipt of concurrent nephrotoxins, including 
aminoglycosides, tacrolimus, meropenem, piperacillin-tazobactam, cyclosporine, scheduled 
NSAIDs (nonsteroidal anti-inflammatory drugs), intravenous (IV) acyclovir, amphotericin B 
deoxycholate, and IV iodinated contrast, was recorded. Steady-state vancomycin serum trough 
concentrations and SCr concentrations were recorded during vancomycin administration and for 
10 days following vancomycin discontinuation. Though an optimal target range for vancomycin 
trough concentrations has not been identified in children, 10 to 15 mg/L was chosen for the purpose 
of this study. Patients’ initial vancomycin trough serum concentrations were categorized as above 
(≥15 mg/L) or within/below (<15mg/L) target range.  
Outcomes 
Acute kidney injury was defined as an increase in SCr by ≥50% from baseline, as adapted from 
pRIFLE criteria.16 SCr was used as a surrogate marker for estimated creatinine clearance to 
minimize calculation steps as these values are inversely proportional.16 Early AKI was categorized 
as occurring within the first 7 days of vancomycin therapy. Late AKI was categorized as AKI 
occurring after the first 7 days of treatment or up to 48 hours following vancomycin 
discontinuation. The primary outcome analyzed was late AKI incidence as determined by pRIFLE 
criteria.  
Data Analysis 
Baseline demographics and clinical characteristics were compared between groups with and 
without late AKI using independent-samples t tests, χ2 analyses, and Mann–Whitney tests for 
nonparametric data. Continuous data were described using mean and standard deviation (SD) for 
4 
 
variables considered to be normally distributed and median and interquartile range (IQR) for 
variables considered to be nonnormally distributed. To determine factors associated with late AKI, 
a logistic regression model was utilized using a forced entry method. The regression model 
included variables considered to be clinically significant or having a P value <0.25 after univariate 
analysis. P values of less than 0.05 were considered to be statistically significant. Statistical 
analyses were conducted using Statistical Package for Social Sciences version 19.0 (SPSS, Inc, 
Chicago, IL).  
Results 
Two hundred fifty-one (N = 251) patients received vancomycin for 8 days or longer and were 
included. Early AKI was identified in 19.9% (50/251); those patients were excluded from further 
study. Of the remaining patients without early AKI, follow-up SCr data were unavailable in 16.9% 
(34/201), leaving 167 patients for final analysis (Figure 1). Patients in the final analysis had a 
median (IQR) age (years) of 2 (1-7) with a minimum to maximum age of 1 month to 17 years. 
Median age did not differ between groups (Table 2). However, there were a higher percentage of 
patients less than 1 year of age in the late AKI group (38.1% vs 18.5%, P = 0.039). Patients in the 
final analysis had a median (IQR) weight (kg) of 12.5 (8.9-23.8). The mean ± SD duration of 
vancomycin treatment was 13.2 ± 5.5 days. Late AKI was identified in 12.6% (21/167) of these 
children. On evaluation of the total incidence of AKI, the early AKI patients were included in the 
analysis, and it was found that 71 of 217 evaluable patients (32.7%) experienced AKI (early or 
late) during their vancomycin treatment course. Table 2 summarizes univariate analysis and 
clinical characteristics of those with no AKI and with late AKI. 
Mean duration of vancomycin treatment was similar between patients with and without AKI, but 
a significantly higher proportion of patients with AKI received vancomycin courses exceeding 2 
weeks duration; 52.4% of patients with late AKI received ≥15 days treatment versus 30.1% of 
patients with no AKI (P = 0.043; observed post hoc power 0.53). There was no difference in initial 
serum trough concentrations between those with and without late AKI (Table 2). Both the no AKI 
and late AKI groups were similar in the percentage of patients maintaining a trough concentration 
≥15 mg/L (10.4% vs 5.3%, P = 0.695). The maximum trough concentration (mg/L) in the no AKI 
group (median [IQR]: 9.7 [7.1-12.8]) was not different than the maximum vancomycin trough 
concentration prior to AKI in the late AKI group (median [IQR]: 10.2 [8.9-14.1], P = 0.264). The 
highest reported trough concentrations for the no AKI and late AKI groups were 45.7 and 18.9 
mg/L, respectively.  
Sepsis or oncologic diagnoses were more common in children with late AKI. Additionally, a 
higher percentage of patients with late AKI received concomitant treatment with IV acyclovir, 
amphotericin products, or piperacillin-tazobactam (Table 1). Piperacillin-tazobactam in 
combination with either an amphotericin product (2.1% vs 14.3%, P = 0.027) or IV acyclovir 
(3.4% vs 19%, P = 0.016) was also encountered with higher frequency in late AKI patients 
compared to those without late AKI. Late AKI patients also received the combination of 
piperacillin-tazobactam plus aminoglycoside more frequently than those patients without AKI, 
though this difference did not reach statistical significance (13% vs 28.6%, P = 0.094).  
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The following variables met criteria as candidate variables to be included in the multivariate 
logistic regression model: age <1 year, maximum trough concentration, vancomycin duration ≥15 
days, oncologic diagnosis, sepsis, receipt of any concurrent nephrotoxin, acyclovir, amphotericin, 
aminoglycoside, and piperacillin-tazobactam. Following multivariate analysis, age <1 year was 
the only factor independently associated with late AKI development (odds ratio = 4.4; 95% 
confidence interval = 1.3-15.4; Table 3).  
Discussion 
Vancomycin utilization and dosing to achieve optimal efficacy and safety has undergone increased 
scrutiny within the past decade. Recommendations for increased empiric vancomycin dosing in 
adult patients resulted from an observation of decreasing susceptibility of methicillin-resistant 
Staphylococcus aureus to vancomycin and consideration of vancomycin’s pharmacodynamics 
parameters.1 In adults, an increased vancomycin dose may be more likely to achieve the goal 
AUC–MIC ratio, which is the main predictor of vancomycin efficacy.1 The AUC–MIC ratio 
cannot be efficiently determined in practice, and the serum trough concentration is recommended 
as an appropriate surrogate with a goal value of 15 to 20 mg/L to correspond with an AUC–MIC 
ratio at least 400:1.1 Pediatric data published after the consensus recommendations bring into 
question the correlation of trough concentration to AUC in children.17,18 Studies by Le et al17 and 
Frymoyer et al18 suggest that in children, a vancomycin trough concentration of 7 to 10 mg/L is 
more closely correlated with an AUC–MIC ratio of 400:1. Targeting higher trough concentrations 
of 15 to 20 mg/L, which would lead to higher AUC–MIC values, could increase the potential for 
vancomycin-associated nephrotoxicity.17,18 Optimal strategies for monitoring vancomycin in 
children remain controversial.19 
Vancomycin has traditionally been viewed as a nephrotoxic agent, and recent reviews are available 
discussing potential explanations for the physiologic basis of vancomycin-associated 
nephrotoxicity, including continued presence of fermentation by-products, direct oxidative stress, 
or allergic interstitial nephritis.12,20 Adult patients experiencing initial vancomycin serum trough 
concentrations ≥15 mg/L or receiving therapy durations ≥7 days may be at higher AKI risk.2⇓⇓⇓-6 
McKamy and colleagues suggested that children with high vancomycin serum trough 
concentrations (≥15 mg/L) were nearly 3 times more likely to have nephrotoxicity compared to 
children with low trough concentrations.8 We have previously published data which suggest that 
an initial trough concentration ≥15 mg/L is a predictor of AKI within the first 7 days of 
vancomycin therapy.7 Bias is a risk in both of these studies as patients with undetected renal 
dysfunction would be expected to have higher vancomycin levels. Vancomycin dose, duration, 
ICU admission, and concurrent nephrotoxin receipt have all been suggested, through logistic 
regression models, to be predictors of AKI in children.7-11 Cies and Shankar suggested that while 
vancomycin duration may be associated with nephrotoxicity, trough concentrations ≥15 mg/L 
were not.11 Unfortunately, differences in study size, design, and cohort characteristics, as well as 
the retrospective nature of all of these studies, have likely contributed to inconsistent findings as 
it pertains to determinants of the true risk factors for vancomycin-associated AKI.  
In our cohort of patients, the late AKI incidence was nearly 13% in patients who received 
vancomycin for at least 8 days (without AKI during the first week of therapy); this incidence is 
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consistent with previous reports, in which rates of late AKI range from 13.7% to 19.4%.6⇓⇓⇓-10 
Though our univariate analysis of clinical factors that may associate with late vancomycin-related 
AKI risk demonstrated findings consistent with other prior studies, our study did not observe those 
same associations in multivariate analysis. Rather, our multivariate analysis suggests that age <1 
year was the only factor independently associated with late AKI. Patients less than 1 year of age 
and receiving vancomycin ≥8 days have a 4.4 times higher odds of developing late AKI than 
patients greater than 1 year. It is possible that some of the factors, such as trough concentration, 
dose, or concurrent administration of additional nephrotoxins, are truly more impactful earlier in 
therapy and perhaps AKI risk evolves over the duration of the vancomycin course. Vancomycin 
duration appears to be a common factor associated with AKI, but a limitation of prior pediatric 
studies is the lack of specific characterization of late AKI and factors associated with it. Studies 
by Cies and Shankar11 and Sinclair et al9 suggest that vancomycin duration is an independent 
predictor of AKI, but neither study identified a particular time point at which AKI risk increases. 
In our cohort of patients receiving at least 8 days of vancomycin therapy, those receiving ≥15 days 
were 2.6 times (95% confidence interval = 1.01-6.44) more likely to experience late AKI than 
those receiving a more modest 8- to 14-day course.  
We found several clinically important associations that are noteworthy. Vancomycin serum trough 
concentrations were not associated with late AKI in the univariate analyses, which could mean 
that other factors beyond vancomycin concentrations are more important in the development of 
late AKI. Significantly fewer children in the late AKI group received NSAIDs. We suspect that 
this finding may be because the most severely ill children (ie, sepsis, oncologic diagnoses, etc), 
those who are highly susceptible to toxic vancomycin effects, are generally not treated with 
NSAIDs. Receipt of concurrent acyclovir, aminoglycosides, amphotericin, or piperacillin-
tazobactam did not reach statistical significance in the multivariate model, but significant 
associations were found following univariate analysis and these should remain clinically important 
considerations for practitioners. In particular, results from recent adult studies have suggested that 
concurrent piperacillin-tazobactam may increase risk for vancomycin-associated AKI.21,22 
Significantly more patients with late AKI in our cohort received combination therapy with 
piperacillin-tazobactam (61.9% vs 38.4%; Table 1). Additionally, our findings suggest that 
piperacillin-tazobactam in combination with either an amphotericin product or IV acyclovir may 
be an important factor in the development of late AKI. Nearly 20% of our patients with an 
oncologic diagnosis were receiving an amphotericin product, over half were receiving piperacillin-
tazobactam, and nearly 10% were receiving both drugs in addition to vancomycin. This 
observation increased the difficult in truly determining if the concurrent receipt of these products 
or the underlying oncologic disease is the true risk factor for AKI. Meropenem was likely a marker 
of severity in our population, but we included it in our analysis as an additional beta-lactam 
antibiotic for comparison to piperacillin-tazobactam.23 The clinical challenge that remains is how 
to most optimally consider these findings along with previous reports to continuously assess an 
ever-changing pediatric patient’s vancomycin-associated AKI risk.  
There are limitations to this study including its retrospective design and the relatively small sample 
size, which may have limited our availability to identify true risk factors for vancomycin-
associated AKI. Our study likely lacked the necessary power due to the small sample size or 
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retrospective design. The inherent limitations of reliance on chart documentation and the variable 
availability of certain data could have affected our findings, as well as the generalizability of our 
findings. Our study, as is common to several of the previous pediatric studies, utilized pRIFLE 
criteria and SCr data to define AKI.7, 9 ,10,16 A drawback of using this is relying on SCr data, which 
may not be reflective of a patient’s true renal function. Transient or small normal variations in a 
child’s SCr, including variance due to acceptable laboratory error, could arguably place the child 
into a pRIFLE category of AKI without clinical evidence supporting nephrotoxicity. Patients in 
this cohort with very low baseline SCr (0.2-0.3 mg/dL) could have been categorized as 
experiencing AKI when it is possible that they experienced an “increase” in SCr due to laboratory 
error or normal variation as opposed to true impairment in glomerular filtration. Though we 
recognize its limitations, we would, however, argue that the merits of the pRIFLE classification 
system as a standardized tool used to monitor for pediatric AKI make it the most robust method 
for AKI identification available for use in a retrospective study such as this. Two different 
laboratory methods for determining SCr values were utilized in our institution during the study 
period. In December of 2008 our institution switched from using enzymatic creatinine assays to 
the isotrope dilution mass spectroscopy traceable Jaffe method. Because incidence of AKI was 
determined based on the percent change from baseline SCr values, we would not suspect this to be 
a significant impairment to our study.  
Conclusions 
In this retrospective cohort study of 167 children who received ≥8 days of vancomycin therapy, 
late AKI occurred in nearly 13% of patients. Age <1 year, vancomycin duration ≥15 days, presence 
of sepsis, presence of oncologic diagnoses, and concomitant administration of IV acyclovir, 
amphotericin, or piperacillin-tazobactam were all factors found to be associated with an increased 
risk of late AKI. Vancomycin trough concentrations were not found to be associated with late AKI. 
Our study highlights the need for improved prospective study of vancomycin-associated AKI risk 
assessment tools. 
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Figure 1 Included patients. 
 
